Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Fostamatinib effectiveness and safety for immune thrombocytopenia in clinical practice

Tomás José González-López, Nuria Bermejo-Vega, Rocío Cardesa-Cabrera, Violeta Martínez-Robles, Gerardo Aguilar-Monserrate, Gloria Pérez-Segura, Abel Domingo, Josefa Luis-Navarro, Sunil Lakhwani, Natalia Acedo, María Luisa Lozano, Silvia Bernat, Ana Torres-Tienza, Ana Ruano, Isidro Jarque, Pilar Galán, Carmen Benet, Shally Marcellini, Reyes Jimenez-Bárcenas, Daniel Martínez-Carballeira, Dunia De Miguel-Llorente, Alvaro Perona-Blázquez, Isabel Gonzalez-Gascón, Elsa Lopez-Ansoar, José María Alonso-Alonso, María Luisa Bengochea-Casado, Francisco Javier Díaz-Gálvez, Ana Moretó, Gemma Moreno-Jiménez, Roberto Hernández-Martin, Erik de Cabo, Julio Dávila-Valls, Amalia Cuesta, Carmen Pastoriza, Gerardo Julio Hermida-Fernández, Covadonga García, Miguel Angel Pozas-Mañas, Carlos Aguilar, Dolores Fernandez-Jimenez, Begoña Navas-Elorza, Carolina López-Santamaría Castro, Alvaro Lorenzo, Xavier Ortín, Marta García, Sonia Piernas, Johana Díaz-Santa, Inmaculada Soto, Drew Provan, Gloria García-Donas Gabaldón

Blood (2024) 144 (6): 646–656.

https://doi.org/10.1182/blood.2024024250

Published: 2024

Journal Articles

Efficacy and Safety of Fostamatinib for Immune Thrombocytopenia in Clinical Practice in Spain: Interim Results of Fostames, Our National Fostamatinib Registry

Blood (2023) 142 (Supplement 1): 2591.

https://doi.org/10.1182/blood-2023-190511

Published: 2023

Journal Articles

Modeling the Development of SRSF2 Mutated Myeloid Malignancies By CRISPR/Cas9 Mediated Genome Engineering of Primary Human Hematopoietic Stem and Progenitor Cells

Gabriel Pabst, Johannes Foßelteder, Angelika Schlacher, Lisa Auinger, Daniel Martinez-Krams, Asiri Ediriwickrema, Karl Kashofer, Christine Beham-Schmid, Hildegard T. Greinix, Albert Woelfler, Peter Schlenke, Heinz Sill, Armin Zebisch, Ravi Majeti, Andreas Reinisch

Blood (2021) 138 (Supplement 1): 2160.

https://doi.org/10.1182/blood-2021-149591

Published: 2021

Journal Articles

Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome–negative adult lymphoblastic leukemia

Josep-Maria Ribera, Mireia Morgades, Juana Ciudad, Pau Montesinos, Jordi Esteve, Eulàlia Genescà, Pere Barba, Jordi Ribera, Irene García-Cadenas, María José Moreno, Daniel Martínez-Carballeira, Anna Torrent, Pilar Martínez-Sánchez, Silvia Monsalvo, Cristina Gil, Mar Tormo, María Teresa Artola, Marta Cervera, José González-Campos, Carlos Rodríguez, Arancha Bermúdez, Andrés Novo, Beatriz Soria, Rosa Coll, María-Luz Amigo, Aurelio López-Martínez, Rosa Fernández-Martín, Josefina Serrano, Santiago Mercadal, Antònia Cladera, Alberto Giménez-Conca, María-Jesús Peñarrubia, Eugènia Abella, Ferran Vall-llovera, Jesús-María Hernández-Rivas, Antoni Garcia-Guiñon, Juan-Miguel Bergua, Beatriz de Rueda, María-José Sánchez-Sánchez, Alfons Serrano, María Calbacho, Natalia Alonso, Jose-Ángel Méndez-Sánchez, Raimundo García-Boyero, Matxalen Olivares, Susana Barrena, Lurdes Zamora, Isabel Granada, Ludovic Lhermitte, Evarist Feliu, Alberto Orfao

Blood (2021) 137 (14): 1879–1894.

https://doi.org/10.1182/blood.2020007311

Published: 2021

Includes: Supplemental data

Journal Articles

Increased mTOR activation in idiopathic multicentric Castleman disease

Daniel J. Arenas, Katherine Floess, Dale Kobrin, Ruth-Anne Langan Pai, Maya B. Srkalovic, Mark-Avery Tamakloe, Rozena Rasheed, Jasira Ziglar, Johnson Khor, Sophia A. T. Parente, Sheila K. Pierson, Daniel Martinez, Gerald B. Wertheim, Taku Kambayashi, Joseph Baur, David T. Teachey, David C. Fajgenbaum

Blood (2020) 135 (19): 1673–1684.

https://doi.org/10.1182/blood.2019002792

Published: 2020

Includes: Supplemental data

Journal Articles

Splenic Marginal Zone Lymphoma: Risk of Transformation, Clinico-Biological Features at Transformation and Prognosis

Blood (2019) 134 (Supplement_1): 4015.

https://doi.org/10.1182/blood-2019-127199

Published: 2019

Journal Articles

Long Term Discontinuation of Eltrombopag after Remission in Primary Immune Thrombocytopenia: 8-Year Follow-up Data from 15 Spanish Centers

Tomas Jose Gonzalez-Lopez, Fernando Fernandez-Fuertes, Maria Cristina Pascual Izquierdo, PhD MD, Isabel Caparros, Silvia Bernat, Carmen Pastoriza, Maria Paz Martínez-Badas, Pável E Olivera, MD, Gonzalo Caballero, MD, Jose Angel Hernandez-Rivas, MD PhD, Daniel Martínez-Carballeira, MD, Inmaculada Soto Ortega, Gloria Perez Segura, Isabel Regalado, Blanca Sánchez-González, Isidro Jarque, Luis Javier garcia Frade, MD, Miguel A. Sanz

Blood (2019) 134 (Supplement_1): 2352.

https://doi.org/10.1182/blood-2019-129274

Published: 2019

Journal Articles

Rituximab and Specific Therapy for Patients with Burkitt's Leukemia and Lymphoma. Results of the BURKIMAB14 Trial from the Spanish Pethema and Geltamo Groups in 80 Patients

Blood (2019) 134 (Supplement_1): 2584.

https://doi.org/10.1182/blood-2019-125683

Published: 2019

Journal Articles

Post-Remission Treatment with Chemotherapy or Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) in Adult Patients with High-Risk (HR) Philadelphia Chromosome-Negative (Ph-neg) Acute Lymphoblastic Leukemia (ALL) According to Their Minimal Residual Disease (MRD). Final Results of the Pethema ALL-HR-11 Trial

Blood (2019) 134 (Supplement_1): 826.

https://doi.org/10.1182/blood-2019-123613

Published: 2019

Journal Articles

Triple Negative Myelofibrosis and Myelodysplastic Syndrome with Fibrosis: Clinico-Biological Characterization and Correlation with Gene Mutations

Juan Gonzalo Correa, MD, Alberto Alvarez-Larrán, MD PhD, Monica Lopez-Guerra, PhD, Juan Carlos Hernandez Boluda, MD PhD, Mar Tormo, MD PhD, María Rozman, MD PhD, Daniel Martínez, MD, Dolors Colomer, PhD, Jordi Esteve, MD PhD, Francisco Cervantes, MD PhD

Blood (2018) 132 (Supplement 1): 4299.

https://doi.org/10.1182/blood-2018-99-115888

Published: 2018

Journal Articles

Characteristics and Outcome of Early T Cell Precursor ALL (ETP-ALL) Patients Treated with High-Risk Spanish Pethema Protocols

Blood (2018) 132 (Supplement 1): 1553.

https://doi.org/10.1182/blood-2018-99-114559

Published: 2018

Journal Articles

Results of the Full Pediatric, Minimal Residual Disease (MRD)-Oriented Trial LAL-RI/2008 for Adolescents and Young Adults (AYA) with Standard Risk (SR), Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL)

Blood (2017) 130 (Supplement 1): 1273.

https://doi.org/10.1182/blood.V130.Suppl_1.1273.1273

Published: 2017

Journal Articles

Is the Outcome of Patients with High Risk T-Cell Acute Lymphoblastic Leukemia Improving in the Era of Pediatric—Inspired Protocols? a Comparison of 2 Consecutive Pethema Trials

Blood (2017) 130 (Supplement 1): 1323.

https://doi.org/10.1182/blood.V130.Suppl_1.1323.1323

Published: 2017

Journal Articles

Recurrent Mutations Of NOTCH Genes In Follicular Lymphoma

Kennosuke Karube, Daniel Martinez, Cristina Royo, PhD, Paola Castillo, Alexandra Valera, Andreas Rosenwald, MD, German Ott, MD, Daniel Esteban, MD, Eva Gine, MD, PhD, Armando Lopez-Guillermo, MD, PhD, Elias Campo

Blood (2013) 122 (21): 4253.

https://doi.org/10.1182/blood.V122.21.4253.4253

Published: 2013

Journal Articles

The Number Of Peg-Asparaginase Doses Administered Is a Determinant Of Relapse Risk In Adult ALL Treated With a Pediatric-Like Regimen

Ibrahim Aldoss, MD, Vinod Pullarkat, MD, Daniel Martinez, MD, Lingyun Ji, Dan Douer, MD

Blood (2013) 122 (21): 3915.

https://doi.org/10.1182/blood.V122.21.3915.3915

Published: 2013

Journal Articles

Targeting of Chronic Lymphocytic Leukemia B Cells with a Novel Monoclonal Antibody to ROR1

Bing CUi, PhD, George F. Widhopf, II, PhD, Jian Yu, PhD, Daniel Martinez, BS, Esther Avery, B.S., Suping Zhang, PhD, Liguang Chen, MD, PhD, Rongrong Wu, Christina C.N. Wu, Ph.D., Charles Prussak, PhD, Thomas J. Kipps, M.D., Ph.D

Blood (2011) 118 (21): 984.

https://doi.org/10.1182/blood.V118.21.984.984

Published: 2011

Journal Articles

Expanded Proliferation Centers (PCs) Identify a Histological Subtype of Chronic Lymphocytic Leukemia (“Accelerated” CLL) with Adverse Clinical Outcome.

Eva Gine, Antonio Martinez, Neus Villamor, Armando Lopez-Guillermo, Mireia Camós, Daniel Martinez, Jordi Esteve, Xavier Calvo, Ana Muntañola, Pau Abrisqueta, Emili Montserrat, Elias Campo, Francesc Bosch

Blood (2009) 114 (22): 2335.

https://doi.org/10.1182/blood.V114.22.2335.2335

Published: 2009

NARROW

Fostamatinib effectiveness and safety for immune thrombocytopenia in clinical practice

Efficacy and Safety of Fostamatinib for Immune Thrombocytopenia in Clinical Practice in Spain: Interim Results of Fostames, Our National Fostamatinib Registry

Modeling the Development of SRSF2 Mutated Myeloid Malignancies By CRISPR/Cas9 Mediated Genome Engineering of Primary Human Hematopoietic Stem and Progenitor Cells

Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome–negative adult lymphoblastic leukemia

Increased mTOR activation in idiopathic multicentric Castleman disease

Splenic Marginal Zone Lymphoma: Risk of Transformation, Clinico-Biological Features at Transformation and Prognosis

Long Term Discontinuation of Eltrombopag after Remission in Primary Immune Thrombocytopenia: 8-Year Follow-up Data from 15 Spanish Centers

Rituximab and Specific Therapy for Patients with Burkitt's Leukemia and Lymphoma. Results of the BURKIMAB14 Trial from the Spanish Pethema and Geltamo Groups in 80 Patients

Triple Negative Myelofibrosis and Myelodysplastic Syndrome with Fibrosis: Clinico-Biological Characterization and Correlation with Gene Mutations

Characteristics and Outcome of Early T Cell Precursor ALL (ETP-ALL) Patients Treated with High-Risk Spanish Pethema Protocols

Results of the Full Pediatric, Minimal Residual Disease (MRD)-Oriented Trial LAL-RI/2008 for Adolescents and Young Adults (AYA) with Standard Risk (SR), Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL)

Is the Outcome of Patients with High Risk T-Cell Acute Lymphoblastic Leukemia Improving in the Era of Pediatric—Inspired Protocols? a Comparison of 2 Consecutive Pethema Trials

Recurrent Mutations Of NOTCH Genes In Follicular Lymphoma

The Number Of Peg-Asparaginase Doses Administered Is a Determinant Of Relapse Risk In Adult ALL Treated With a Pediatric-Like Regimen

Targeting of Chronic Lymphocytic Leukemia B Cells with a Novel Monoclonal Antibody to ROR1

Expanded Proliferation Centers (PCs) Identify a Histological Subtype of Chronic Lymphocytic Leukemia (“Accelerated” CLL) with Adverse Clinical Outcome.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only